Searched for
ZYDUS SEMAGLUTIDE APPROVAL
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practicesIndia's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthor...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss marketAlkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is ...
- Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expiresNatco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the inn...
- Stocks in news: Manappuram Finance, Kotak Bank, Nazara Technologies, United BreweriesIndian markets continued their recovery for a third straight session, with Nifty approaching the 23,800-24,000 resistance zone. Key stocks ...
- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Zydus plans launch of semaglutide generic in reusable pen formZydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under...
- 2025 in the rearview: A year of tumult and triumphIndia's economy in 2025 faced challenges from US tariffs and foreign investor exits. Despite these, domestic demand and reforms fueled stro...
- Intense Lilly, Novo rivalry throws India weight-loss drug race wide openEli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
Load More
